OPM Biosciences

Executive Summary

OPM Biosciences is a Shanghai-based preclinical biotech founded in 2020, specializing in proteomics-driven drug discovery for oncology and immunology. Its platform integrates high-throughput mass spectrometry with AI-based target validation to identify novel biologic targets. The company's approach aims to accelerate the development of next-generation therapeutics by directly analyzing protein expression and interactions in disease tissues. With a lean team of 10-50 employees, OPM Biosciences represents a typical early-stage Chinese biotech leveraging advanced proteomics to address unmet medical needs in cancer and immune disorders. The company's progress and valuation remain undisclosed, but its focus on AI-enhanced proteomics positions it within a rapidly growing field. No pipeline candidates have been publicly disclosed, suggesting the company is still in the target discovery and validation phase. The primary near-term focus will be on advancing its most promising targets toward preclinical proof-of-concept studies and seeking partnerships or financing to support further development.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q1 2027Lead Candidate Nomination for IND-Enabling Studies50% success
• Q4 2026Research Collaboration with Major Pharma Company40% success